Their findings suggest that anti-PD-1 therapy is particularly effective in patients with a pre-existing TEMRA phenotype, and that HCMV infection may condition the immune system to respond more robustly by driving cytotoxic differentiation and effector function in CD8+ T-cells [99]. This evidence concerns the gene CD8A and cytomegalovirus infection.